“Checkpoint Kinase Inhibitor Pipeline” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Checkpoint Kinase Inhibitor pipeline landscape is provided, which includes the topic overview and Checkpoint Kinase Inhibitor mechanism of action. The assessment part of the report embraces, in-depth Checkpoint Kinase Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes the product description, mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
What are Checkpoint Kinases?
The development of Checkpoint Kinase Inhibitors to treat cancer has been a major objective in drug discovery. Checkpoint Kinases are protein kinases, Chk1 and Chk2, Ser/Thr protein kinases, which function as key regulatory kinases in cellular DNA damage response pathways limiting cell-cycle progression in the presence of DNA damage.
Checkpoint kinase 1 (CHK1) is an oncology target of significant current interest. Inhibition of CHK1 abrogates DNA damage-induced cell cycle checkpoints and sensitizes p53 deficient cancer cells to genotoxic therapies.
Which are the key players involved in development of Checkpoint Kinase Inhibitor Pipeline drugs?
Key Players involved in Checkpoint Kinase Inhibitor Pipeline are Boehringer Ingelheim, CanBas, Vernalis, Sierra Oncology, Pharos I&BT Co, Eli Lilly and company, Sentinel Oncology, IMPACT Therapeutics, Pink Biopharma, and others.
Which are Checkpoint Kinase Inhibitor Pipeline Drugs?
Drug
Company
Clinical Phase
RoA
SRA737
Sierra Oncology
I/II
Oral
CBP501
CanBas
I
Intravenous
PHI 101
Pharos I&BT
BI 765063
Boehringer Ingelheim
Parenteral
Prexasertib
Eli Lilly and Company
NA
SOL-578
Sentinel Oncology
Preclinical
V158411
Vernalis
Research Programme:
Checkpoint Kinase Inhibitors
Pink Biopharma
Discovery
IMP 10
IMPACT Therapeutics
Scope of the report
For more information on Checkpoint Kinase Inhibitors, visit Checkpoint Kinase Inhibitor Pipeline Analysis
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/